Trial of aflibercept for pancreatic cancer halted

09/14/2009 | Reuters

A late-stage trial on the use of aflibercept in combination with gemcitabine as first-line treatment of pancreatic cancer was discontinued because of disappointing results. The drugmakers said they will continue testing aflibercept's effectiveness against metastatic colorectal cancer, metastatic prostate cancer and nonsmall-cell lung cancer.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC